Key result
Oral LAV-BPIFB4 improves cardiac contractility and capillarity in aging and diabetic mice.
Why the study?
There is no therapy to prevent heart dysfunction in aging and diabetic individuals, despite their increased risk for heart failure with preserved ejection fraction.
Does orally administered LAV-BPIFB4 protein improve cardiac function in aging and diabetic murine models of cardiomyopathy?
RCT
randomized
Does orally administered LAV-BPIFB4 protein improve cardiac function in aging and diabetic murine models of cardiomyopathy?
Oral administration of the longevity-associated variant of BPIFB4 protein improves cardiac function and reduces senescence in aging and diabetic mouse models of cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Oral LAV-BPIFB4 improved cardiac function in aged and diabetic mouse HFpEF models; leaves open human translation and requires prospective trials.
AIMS: Aging is influenced by genetic determinants and comorbidities, among which diabetes increases the risk for heart failure with preserved ejection fraction. There is no therapy to prevent heart dysfunction in aging and diabetic individuals. In previous studies, a single administration of the longevity-associated variant (LAV) of the human BPIFB4 gene halted heart decline in older and type 2 diabetic mice. Here, we asked whether orally administered LAV-BPIFB4 protein replicates these benefits. MATERIALS AND METHODS: In two controlled, randomized studies, 18-month-old male C57BL/6 J mice and 9-week-old C57BLKS/J-Leprdb/Leprdb/Dock7 + [db/db] mice of both sexes underwent baseline echocardiography. They then received a recombinant purified LAV-BPIFB4 protein (3 µg/animal, every three days) or vehicle by gavage. After 30 days, the animals underwent echocardiography, and the hearts were collected post-termination for histology. RESULTS: All the animals completed the study except one female diabetic mouse, which was culled prematurely because tooth malocclusion caused eating problems. There was no effect of the LAV-BPIFB4 protein on body weight in the two studies or glycosuria in the diabetic study. In aging mice, LAV-BPIFB4 increased myocardial Bpifb4 expression, improving heart contractility and capillarity while reducing perivascular fibrosis and senesce. In male diabetic mice, LAV-BPIFB4 therapy improved systolic function, microvascular density, and senescence, whereas the benefit was limited to systolic function in females. CONCLUSIONS: This study shows the feasibility and efficacy of a variant protein associated with human longevity in contrasting pivotal risk factors for heart failure in animal models. The diabetic study revealed that sex influences the treatment efficacy.
No takes yet. Share an insight, caveat, or question.
Alvino et al. (2024) conducted an RCT in Cardiomyopathy with preserved ejection fraction risk in aging and diabetes. LAV-BPIFB4 protein vs. vehicle was evaluated on Echocardiographic and histological parameters (heart contractility, capillarity, perivascular fibrosis, senescence). Oral administration of LAV-BPIFB4 protein improved heart contractility and capillarity in aging mice, and improved systolic function in diabetic mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: